Ahmed Dahmani

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC.

Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC.

Journal: Cancer science

Published: September 25, 2025

Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal Cells.

Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal Cells.

Journal: Cancers

Published: June 02, 2025

Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients.

Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients.

Journal: Cancer research

Published: March 05, 2025

Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients.

Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients.

Journal: Cancer research

Published: March 05, 2025

Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study.

Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study.

Journal: Cancer research communications

Published: August 21, 2024

Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay.

Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay.

Journal: NPJ breast cancer

Published: August 07, 2024

Targeting ferroptosis resistance resensitizes metastatic HR+HER2- breast cancer cells to palbociclib-hormone therapy.

Targeting ferroptosis resistance resensitizes metastatic HR+HER2- breast cancer cells to palbociclib-hormone therapy.

Journal: Cancer communications (London, England)

Published: March 15, 2024

Cellular origin and clonal evolution of human dedifferentiated liposarcoma.

Cellular origin and clonal evolution of human dedifferentiated liposarcoma.

Journal: Nature communications

Published: December 13, 2023

TFEB triggers a matrix degradation and invasion program in triple-negative breast cancer cells upon mTORC1 repression.

TFEB triggers a matrix degradation and invasion program in triple-negative breast cancer cells upon mTORC1 repression.

Journal: Developmental cell

Published: November 13, 2023

The mutational landscape of skull base and spinal chordomas and the identification of potential prognostic and theranostic biomarkers.

The mutational landscape of skull base and spinal chordomas and the identification of potential prognostic and theranostic biomarkers.

Journal: Journal of neurosurgery

Published: September 20, 2022

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers.

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers.

Journal: Nature communications

Published: August 11, 2022

Author Correction: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.

Author Correction: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.

Journal: Communications biology

Published: July 05, 2022

Showing 1-12 of 31

Last Updated: 09/26/2026